celecoxib : Related Words Words similar in meaning to celecoxib
- celecoxib«
- rheumatoid arthritis«
- celebrex«
- polyp«
- cox-2«
- osteoarthritis«
- pfizer«
- non-steroidal anti-inflammatory drug«
- nsaid«
- menstruation«
- nonselective nsaid«
- risk«
- drug«
- cox-1«
- searle«
- aspirin«
- cox-2 inhibitor«
- pharmacia«
- naproxen«
- fda«
- cardiovascular event«
- cox-2 inhibition«
- patient«
- acetaminophen«
- ibuprofen«
- shortest duration«
- inhibition«
- anticancer effect«
- rofecoxib«
- inflammatory drug«
- monsanto«
- compound«
- potency«
- acute pain«
- individual patient goal«
- superior selectivity«
- cox-2 inhibitory activity«
- conventional nsaid«
- inflammation«
- patent«
- pain relief«
- rochester v. g.d. searle«
- rectal polyp«
- major vascular event«
- dr. reuben«
- caution«
- cox-2 enzyme«
- painful menstruation«
- people«
- selectivity«
- lowest effective dose«
- study«
- pyrazole«
- cutaneous reaction«
- postoperative pain«
- juvenile rheumatoid arthritis«
- vioxx«
- familial adenomatous polyposis«
- drug administration«
- week gestation«
- prior history«
- cancer«
- spondylitis«
- public citizen«
- discovery«
- cir«
- university«
- diuretic«
- perforation«
- warning«
- ulcer«
- bleeding«
- structure«
- byu«
- fed«
- hypertension«
- colon«
- pain«
- –so2nhch3 substituent«
- u television ad«
- u re44048«
- sulfonamide oxygen«
- sulfamoylphenyl«
- role celecoxib«
- polyp growth«
- platelet activator«
- pharmacia study«
- pharmacia employee«
- pfizer ownership«
- other cox-2-selective inhibitor«
- onsenal«
- major patent dispute«
- kidney hemodynamics«
- inhibitory concentration-50«
- individual cardiovascular risk profile«
- gi adverse event«
- gastrointestinal adverse drug reaction«
- fap family«
- drug ’s anticancer effect«
- dr. scott reuben«
- credible academic medical center«
- cox-2 selective nonsteroidal anti«
- cox-2 selective inhibition«
- cox-1 complex«
- contractual royalty«
- concomitant gastroprotective therapy«
- celecoxib serum level«
- celecoxib increase lithium plasma level«
- celecoxib generic«
- celecoxib cost«
- brand name celebrex«
- aspirin nonsteroidal anti«
- apc trial«
- american heart association warning«
- affect prothrombin time«
- adverse cardiovascular thrombotic event«
- adequate cox-2 inhibition«
- active cox-2«
- -minute advertisement«
- % polyp recurrence reduction«
- prescription«
- adverse effect«
- united state pat«
- sulfonamide moiety«
- skin adverse event«
- several dozen analog«
- selective reversible inhibitor«
- searle research«
- scale randomized clinical trial«
- reputable investigator«
- prostaglandin precursor«
- pocket region«
- myocardial infarction rate«
- inflammatory drug celecoxib«
- ile523«
- gastrointestinal risk«
- efficacy studies«
- difluoromethyl«
- cv risk«
- current medical recommendation«
- cox-2-selective inhibitor«
- cox-2 inhibitor rofecoxib«
- antitumor potency«
- acute pain relief«
- para«
- tumor«
- upper gastrointestinal complication«
- term cardiovascular risk«
- stronger anticancer activity«
- scott s. reuben«
- nonfatal myocardial infarction«
- low steric hindrance«
- hematologic effect«
- head clinical trial«
- fluoromethyl«
- famous target«
- cytochrome p450 2c9«
- cancer reduction«
- cadherin-11«
- analgesic function«
- favor«
- comparison«
- gi«
- rate«
- % increase«
- pfizer drug«
- onset hypertension«
- nonfatal stroke«
- gi toxicity«
- gi disease«
- gastrointestinal event«
- respective compound«
- pfizer ’s«
- methyl substitution«
- inflammatory«
- daniel l. simmons«
- concurrent therapy«
- alternate therapy«
- ulcer disease«
- thrombogenesis«
- severe liver impairment«
- risk similar«
- philip needleman«
- patent expiry«
- cyclooxygenase enzyme«
- incidence«
- robust increase«
- randomized control study«
- methoxyphenyl«
- medical research division«
- hip osteoarthritis«
- gastrointestinal adverse effect«
- fraudulent data«
- bacterial lipopolysaccharides«
- activity relationship«
- cardiovascular safety«
- sulfa allergy«
- malignant tumor cell«
- gastrointestinal complication«
- double patenting«
- debilitated patient«
- allergy«
- therapy«
- celebra«
- pregnancy category«
- oral capsule«
- class effect«
- cerebrovascular event«
- term pain relief«
- coxibs«
- exfoliative dermatitis«
- colon polyp«
- baystate medical center«
- lowest dose«
- method«
- therapeutic concentration«
- cancer cell type«
- gastrointestinal mucosa«
- tumor promoter«
- lisinopril«
- intracellular component«
- pharmaceutical company pfizer«
- sale«
- adjacent position«
- cardioprotective effect«
- crucial data«
- consumer advertising«
- rochester«
- essence«
- risk people«
- drug interactions«
- complication«
- mental illness«
- g. d. searle«
- various modification«
- enzyme«
- trifluoromethyl«
- central ring«
- typical month«
- musculoskeletal pain«
- capsule form«
- scale clinical trial«
- partial thromboplastin time«
- additional target«
- thromboxane a2«
- lyrica«
- cardiovascular risk factor«
- black box warning«
- alleged action«
- severe allergy«
- result«
- research«
- cardiovascular effect«
- johnson syndrome«
- drug molecule«
- heart attack«
- valdecoxib«
- Celebrex«
- Cox-2 inhibitor«
- 4-sulfamoylphenyl«
- 5-pyrazol system«
- 4-(methylsulfonyl)phenyl«
- 2c9 inhibitor«
- 1-pyrazol substituent«
- 1,5-diarylpyrazole moiety«
- 4-methyl«
- 3-position«
- Vioxx«
- Bextra«
